Tara Menon1, Anita Afzali2. 1. The Ohio State University Inflammatory Bowel Disease Center, Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, USA. tara.menon@osumc.edu. 2. The Ohio State University Inflammatory Bowel Disease Center, Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Abstract
PURPOSE OF REVIEW: This review addresses our current knowledge of immune-mediated colitis (IMC) and offers a practical guide to its management. RECENT FINDINGS: Due to the similarity in clinical, endoscopic, and histologic findings between IMC and inflammatory bowel disease (IBD), gastroenterologists have tailored their approach to IMC management to that of IBD. Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that augment the T-cell anti-tumor response of the immune system and have demonstrated their importance in the treatment of a wide range of malignancies. With the growing benefits of ICIs, there are immune-related adverse events (irAEs) that mirror many known autoimmune diseases. Diarrhea and IMC are the most common and severe irAEs noted. No standardized guidelines exist in the management of these irAEs.
PURPOSE OF REVIEW: This review addresses our current knowledge of immune-mediated colitis (IMC) and offers a practical guide to its management. RECENT FINDINGS: Due to the similarity in clinical, endoscopic, and histologic findings between IMC and inflammatory bowel disease (IBD), gastroenterologists have tailored their approach to IMC management to that of IBD. Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that augment the T-cell anti-tumor response of the immune system and have demonstrated their importance in the treatment of a wide range of malignancies. With the growing benefits of ICIs, there are immune-related adverse events (irAEs) that mirror many known autoimmune diseases. Diarrhea and IMC are the most common and severe irAEs noted. No standardized guidelines exist in the management of these irAEs.
Authors: Chana Weinstock; Sean Khozin; Daniel Suzman; Lijun Zhang; Shenghui Tang; Sakar Wahby; Kirsten B Goldberg; Geoffrey Kim; Richard Pazdur Journal: Clin Cancer Res Date: 2017-06-13 Impact factor: 12.531
Authors: L Marthey; C Mateus; C Mussini; M Nachury; S Nancey; F Grange; C Zallot; L Peyrin-Biroulet; J F Rahier; M Bourdier de Beauregard; L Mortier; C Coutzac; E Soularue; E Lanoy; N Kapel; D Planchard; N Chaput; C Robert; F Carbonnel Journal: J Crohns Colitis Date: 2016-01-18 Impact factor: 9.071
Authors: Kimberly E Beck; Joseph A Blansfield; Khoi Q Tran; Andrew L Feldman; Marybeth S Hughes; Richard E Royal; Udai S Kammula; Suzanne L Topalian; Richard M Sherry; David Kleiner; Martha Quezado; Israel Lowy; Michael Yellin; Steven A Rosenberg; James C Yang Journal: J Clin Oncol Date: 2006-05-20 Impact factor: 44.544
Authors: Eduard Cornelis Verschuren; Alfonsus Johannes van den Eertwegh; Janneke Wonders; Rob Michel Slangen; Foke van Delft; Adriaan van Bodegraven; Andra Neefjes-Borst; Nanne Klaas de Boer Journal: Clin Gastroenterol Hepatol Date: 2015-12-31 Impact factor: 11.382